LEUKOTREAT
Therapeutic challenge in Leukodystrophies: Translational and ethical research towards clinical trials
| Coordinatore | UNIVERSITE D'AUVERGNE CLERMONT-FERRAND 1
Organization address
address: Boulevard Francois Mitterand 49 contact info |
| Nazionalità Coordinatore | France [FR] |
| Sito del progetto | http://leukotreat.eu/ |
| Totale costo | 9˙249˙281 € |
| EC contributo | 5˙978˙126 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-03-01 - 2013-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITE D'AUVERGNE CLERMONT-FERRAND 1
Organization address
address: Boulevard Francois Mitterand 49 contact info |
FR (Clermont-Ferrand) | coordinator | 796˙258.60 |
| 2 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 671˙624.00 |
| 3 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 401˙758.00 |
| 4 |
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Organization address
address: Via Olgettina 60 contact info |
IT (MILANO) | participant | 388˙600.00 |
| 5 |
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203 contact info |
ES (L'HOSPITALET DE LLOBREGAT) | participant | 376˙282.00 |
| 6 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 359˙380.00 |
| 7 |
UNIVERSITAETSKLINIKUM BONN
Organization address
address: Sigmund-Freud-Strasse 25 contact info |
DE (BONN) | participant | 352˙480.00 |
| 8 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 337˙888.00 |
| 9 |
Soluscience SA
Organization address
address: Biopole Clermont-Limagne contact info |
FR (Saint-Beauzire) | participant | 300˙800.00 |
| 10 |
FRANCE EUROPE INNOVATION
Organization address
address: RUE DES RENAUDES 32 contact info |
FR (PARIS) | participant | 277˙119.00 |
| 11 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 254˙800.00 |
| 12 |
UNIVERSITE PARIS DESCARTES
Organization address
address: Rue de l'Ecole de Medecine 12 contact info |
FR (PARIS) | participant | 237˙840.00 |
| 13 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 215˙519.78 |
| 14 |
UNIVERSITY OF NEW SOUTH WALES
Organization address
address: ANZAC PARADE contact info |
AU (SYDNEY) | participant | 207˙287.00 |
| 15 |
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Organization address
address: Martinistrasse 52 contact info |
DE (HAMBURG) | participant | 112˙920.34 |
| 16 |
UNIVERSITE PARIS DIDEROT - PARIS 7
Organization address
address: RUE THOMAS MANN 5 contact info |
FR (PARIS) | participant | 107˙304.00 |
| 17 |
ISTITUTO GIANNINA GASLINI
Organization address
address: VIA GEROLAMO GASLINI 5 contact info |
IT (GENOVA) | participant | 100˙300.00 |
| 18 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 93˙825.76 |
| 19 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 89˙886.00 |
| 20 |
TROPHOS SA
Organization address
address: PARC SCIENTIFIQUE LUMINY CASE 931 contact info |
FR (MARSEILLE CEDEX 9) | participant | 84˙714.80 |
| 21 |
OSPEDALE PEDIATRICO BAMBINO GESU
Organization address
address: PIAZZA SAN ONOFRIO 4 contact info |
IT (ROMA) | participant | 84˙612.00 |
| 22 |
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
Organization address
address: VIA CELORIA 11 contact info |
IT (MILANO) | participant | 52˙361.91 |
| 23 |
ASSOCIATION EUROPEENNE CONTRE LES LEUCODYSTROPHIES
Organization address
address: Rue Mi-les-Vignes 2 contact info |
FR (Laxou) | participant | 51˙164.80 |
| 24 |
Fondazione Centro San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 23˙400.00 |
| 25 |
UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Organization address
address: Langenbeckstrasse 1 contact info |
DE (Mainz) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Leukodystrophies (LDs) are inherited rare neurodegenerative diseases of the white matter and its main component, the myelin, that are affecting predominantly children. Severity of the disease is related to the axonal dysfunction due to myelin deficiency or destruction. Despite the achievement of remarkable advances made in the past decade, there is no current curative therapy. The development of therapeutic approaches for myelin repair and neuroprotection constitutes the main objective of the LeukoTreat project. Indeed LDs constitute prototypic pathologies to tackle myelin formation/destruction issues as well as glial cells dysfunctions in neurodegeneration. The global aim is to promote the development of therapeutic strategies for the largest number of LD affected patients and further applications to more common white matter disorders and finally neurodegenerative diseases. For this purpose, the project will combine the expertise of (i) recognized European research teams in the field of White Matter diseases (COST Myelinet), (ii) high-technology SMEs, (iii) experts in medical ethics and (iv) LD patients and families associations. To develop efficient therapies, the LeukoTreat project is based on 5 complementary approaches consisting in: (i) collecting information on the epidemiology, the natural history, the genotype/phenotype correlation of LDs for at least 500 patients; (ii) validating/identifying biomarkers for therapeutic decisions/follow up to isolate new therapeutic targets; (iii) developing pharmacological strategies with the ultimate objective to launch at least 4 pharmacological clinical trials during 5 years following the project; (iv) developing innovative gene and cell therapies with the ultimate objective to launch at least 3 clinical trials during the next 5 years; (v) tackling ethical impacts of the proposed therapeutic challenges by integrating the participation of patients driven by a well-experienced research team strongly skilled in ethics'
Introduzione (Teaser)
Leukodystrophies are rare genetic disorders characterised by degeneration of the white matter of the brain. European researchers joined forces to develop innovative therapies against these debilitating disorders.